Clinical Trials Logo
  1. Home
  2. Urothelial Carcinoma Ureter
  3. NCT06120387

Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer

Locally Advanced Clinical Trial

Official title:
Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer

Clinical Trial Summary

In this study, we propose to conduct an ambispective study to analyze the safety of preserved renal unit surgery combined with postoperative adjuvant radiotherapy in patients with limited stage ureteral cancer with high risk factors, and the efficacy analysis compared with traditional radical surgery. It is hoped that a treatment method that preserves patients' renal function to improve the tolerance of subsequent drug therapy without decreasing the effect of tumor treatment can be achieved in patients with high-risk factors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06120387
Study type Observational
Source Peking University First Hospital
Contact
Status Recruiting
Phase
Start date November 10, 2023
Completion date November 9, 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05679674 - Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer N/A
Recruiting NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Phase 1/Phase 2
Not yet recruiting NCT05576480 - SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer Phase 2
Completed NCT01216345 - Cetuximab + Gemox in Biliary Tract Cancer Phase 2
Completed NCT00911170 - PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study Phase 3
Completed NCT00378313 - A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer Phase 2
Active, not recruiting NCT05868317 - Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer Phase 2
Terminated NCT01318642 - Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas Phase 2
Completed NCT01327612 - Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) Phase 2
Completed NCT03644056 - Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors Phase 1
Active, not recruiting NCT03093922 - A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer Phase 2
Recruiting NCT05766800 - Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT06416007 - Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors Phase 2
Active, not recruiting NCT03024489 - Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT05877573 - Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer N/A
Terminated NCT00819169 - QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors Phase 1/Phase 2
Recruiting NCT06020430 - Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy N/A
Active, not recruiting NCT06102057 - PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC Phase 2
Recruiting NCT05802394 - The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer N/A
Recruiting NCT05763641 - TAD After Chemotherapy in Locally Advanced Breast Cancer